Viela Bio, China's Hansoh pen development pact potentially worth $220M-plus | Fierce Biotech
Viela Bio Inc (VIE) Investor Presentation - Slideshow (NASDAQ:VIE) | Seeking Alpha
Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results | citybiz
20 Things You Didn't Know About Viela Bio
Viela Bio's Spinout Story Reveals A Roadmap for Growth Ahead · BioBuzz
Viela Bio | LinkedIn
Viela Bio - HBM Partners AG
Viela Bio Spins Out of AstraZeneca's MedImmune with $250 Million Series A Funding | BioSpace
Horizon Therapeutics agrees to acquire biotechnology firm Viela Bio
Viela Bio to be acquired by Horizon Therapeutics for $3.1 billion - Washington Business Journal
Xconomy: Viela Bio Gets FDA Green Light for Rare Autoimmune Disease Treatment
Viela Bio - Crunchbase Company Profile & Funding
Horizon Therapeutics to acquire Viela Bio for $3bn
Horizon Therapeutics to Expand Pipeline, R&D with $3B Viela Bio Acquisition
Horizon To Snap Up Viela Bio For $3B; Shares Climb
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio | Horizon Therapeutics plc
Viela Bio, Inc. - AnnualReports.com
$3.05 Billion: Horizon Therapeutics Acquires Viela Bio
Viela Bio, Inc.Analytics - Traffic, Statistics and Competitor tracking | WatchMyCompetitor
Gaithersburg's Viela Bio is set to be acquired for $3.05B - Technical.ly
Viela Bio's Uplizna Granted FDA Approval As Company's First Commercial Product · BioBuzz
Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition - PMLiVE
Viela Bio officially goes public - Washington Business Journal
